Markers of oxidative stress in children with Down syndrome

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 3, 2006, Pages 306-310

  Žitňanová, Ingrid ^a   Korytár, Peter ^a   Sobotová, Hana ^a   Horáková, L'ubica ^b   Šustrová, Mária ^c   Pueschel, Siegfried ^d   Ďuračková, Zdeňka ^a,e  

^a Physics and Informatics   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c Research Base of the Slovak Medical University   (Slovakia)

^d BROWN UNIVERSITY   (United States)

^e Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

Author keywords

4 hydroxy 2 nonenal; Antioxidants; Carbonyls; Down syndrome; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; CARBONYL DERIVATIVE; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; ARTICLE; ASSAY; CHROMOSOME 21; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FERRIC REDUCING ABILITY OF PLASMA ASSAY; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEFECT; SCHOOL CHILD;

ALDEHYDES; ANTIOXIDANTS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEINS; SUPEROXIDE DISMUTASE;

EID: 33644821558     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.053     Document Type: Article

References (38)

1. Sinet PM. Metabolism of oxygen derivatives in Down's syndrome. Ann NY Acad Sci 1982;396:83-94.
2. Jenner P. Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Pathol Biol 1996;15:57.
3. DeHaan JB, Newman JD, Kola I. Cu/Zn superoxide dismutase mRNA and enzyme activity and susceptibility to lipid peroxidation, increases with aging in murine brains. Brain Res Mol Brain Res 1992;13:179-87.
4. Muchová J, Šustrová M, Garaiová I, Liptáková A, Blaží-ček P, Kvasnička P, et al. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med 2001;31:499-508.
5. Garaiová I, Muchová J, Šustrová M, Blažíček P, Sivoňová M, Kvasnička P, et al. The relationship between antioxidant systems and some markers of oxidative stress in persons with Down syndrome. Biologia 2004;59:781-8.
6. Tan YH, Tischfield J, Ruddle FH. The linkage of genes for human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G21. J Exp Med 1993;137:317-30.
7. Ďuračková Z, Korytár P, Sivoń ová M, Ursínyová M, Šustrová M. Does Cu/Zn-superoxide dismutase exhibit a nondismutase activity? Curr Top Biophys 2000;24:39-43.
8. Žitňanová I, Korytár P, Aruoma OI, Šustrová M, Garaiová I, Muchová J, et al. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clin Chim Acta 2004;341:139-46.
9. Benzie F, Strain JJ. Ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Med Biochem 1996;239:70-6.
10. Buss H, Chan TP, Sluis KB, Domingan NM, Winterbourn CC. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997;23:361-6.
11. Sitte N, Merker K, Grune T. Proteasome-dependent degradation of oxidized proteins in MRC-5 fibroblasts. FEBS Lett 1998;440:399-402.
12. Kinter M. Quantitative analysis of 4-hydroxy-2-nonenal. In: Punchard NA, Kelly FJ, editors. Free radicals. A practical approach. Oxford: IRL Press, Oxford University Press, 1996.
13. Moreira PI, Smith MA, Zhu X, Nunomura A, Castellani RJ, Perry G. Oxidative stress and neurodegeneration. Ann NY Acad Sci 2005;1043:545-52.
14. Zarkovic K. 4-Hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 2003;24:293-303.
15. Chapman ML, Rubin BR, Gracy RW. Increased carbonyl content of proteins in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1989;16:15-9.
16. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 1991;88:347-53.
17. Gladstone IM, Levine RL. Oxidation of proteins in neonatal lungs. Pediatrics 1994;93:764-8.
18. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mruno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996;93:2696-701.
19. Uchida K, Toyokuni S, Kishikawa S, Oda H, Hiaia H, Stadtman ER. Michael addition-type 4-hydroxy-2-nonenal adducts in modified low-density lipoproteins: markers for atherosclerosis. Biochemistry 1994;33:12487-94.
20. Balcz B, Kirchner L, Cairns N, Fountoulakis M, Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transm 2001;16(Suppl):193-201.
21. Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Bricarelli F, et al. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 1998;243:849-51.
22. Ďuračková Z, Šustrová M, Korytár P, Muchová J, Garaiová I, Liptáková A. What is the real function of Cu/Zn-superoxide dismutase? Free Radic Biol Med 2000;29(Suppl):abstract 29 (Proceedings of the 7th Annual Meeting of the Oxygen Society).
23. Ciechanover A, Orian A, Schwartz AL. The ubiquitin-mediated proteolytic pathway. Mode of action and clinical implications. J Cell Biochem 2000;34(Suppl):4051.
24. Stadtman ER. Protein oxidation and aging. Science 1992;257:1220-4.
25. Dean RT, Armstrong S, Fu S, Jessup W. Oxidized proteins and their enzymatic proteolysis in eukaryotic cells: a critical appraisal. In: Nohl H, Esterbauer H, Rice-Evans C, editors. Free radicals in the environment, medicine and toxicology. London: Richelieu Press, 1994:47-79.
26. Friguet B, Szweda LI. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein. FEBS Lett 1997;405:21-5.
27. Sitte N, Merker K, von Zglinicki T, Grune T. Protein oxidation and degradation during proliferative senescence of human MRC-5 fibroblasts. Free Radic Biol Med 2000;28:701-8.
28. Hoff HF, O'Neil J, Chisolm GM III, Cole TB, Quehenberger O, Esterbauer H, et al. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 1989;9:538-49.
29. Kinter M, Robinson CS, Grimminger LC, Gillies PJ, Shimshick EJ, Ayers C. Whole blood and plasma concentrations of 4-hydroxy-2-nonenal in Watanabe heritable hyperlipidemic versus New Zealand White rabbits. Biochem Biophys Res Commun 1994;199:671-5.
30. Sullivan SJ, Roberts RJ, Spitz DR. Replacement of media in cell culture alters oxygen toxicity: possible role of lipid aldehydes and glutathione transferase in oxygen toxicity. J Cell Physiol 1991;147:427-33.
31. Srivastava S, Chandra A, Wang LF, Seifert WEJR, Dague BB, Ansari NH, et al. Metabolism of the lipid peroxidation product 4-hydroxy-trans-2-nonenal in isolated perfused rat heart. J Biol Chem 1998;273:10893-900.
32. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU. 4-Hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Antioxid Redox Signal 1999;1:255-84.
33. Hartley DP, Ruth JA, Petersen DR. The hepatocellular metabolism of 4-hydroxynonenal by alcohol dehydrogenase, aldehyde dehydrogenase and glutathione-S-transferases. Arch Biochem Biophys 1995;316:197-205.
34. Uchida K, Stadtman ER. Quantitation of 4-hydroxynonenal protein adducts. Methods Enzymol 1994;233:371-80.
35. Horáková E, Ondrejičková O, Vajdová M, Korytár P, Ďuračková Z, Schaur RJ. Mechanisms of iron-induced oxidative modifications of creatine kinase in rat brain in vitro. Possible involvement of HNE. Gen Physiol Biophys 2002;21:327-36.
36. Pratico D, Iuliano L, Amerio G, Tang LX, Rokach J, Sabatino G, et al. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 2000;48:795-8.
37. Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 1998;25:1044-8.
38. Carratelli M, Porcaro L, Ruscica M, De Simone E, Bertelli AA, Corsi MM. Reactive oxygen metabolites and prooxidant status in children with Down's syndrome. Int J Clin Pharmacol Res 2001;21:79-84.